Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma (Q44831889)

6 December 2017

title

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma (English)

1 reference

6 December 2017

1 reference

1 reference

1 reference

6 December 2017

Catherine Thieblemont

object named as

Catherine Thieblemont

1 reference

6 December 2017

Anne-Sophie Michallet

object named as

Anne-Sophie Michallet

1 reference

6 December 2017

Daciana Antal

1 reference

6 December 2017

Laurence Lacotte-Thierry

1 reference

6 December 2017

Daniel Espinouse

1 reference

6 December 2017

Catherine Traulle

1 reference

6 December 2017

Fadhela Bouafia-Sauvy

1 reference

6 December 2017

Christine Giraud

1 reference

6 December 2017

Gilles Salles

1 reference

6 December 2017

François Guilhot

1 reference

6 December 2017

Bertrand Coiffier

1 reference

6 December 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

6 December 2017

1 reference

6 December 2017

volume

104

1 reference

6 December 2017

1 reference

6 December 2017

page(s)

1434-1441

1 reference

Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation

6 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Mantle cell lymphoma: a therapeutic dilemma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Mantle cell lymphoma: a retrospective study of 121 cases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Phase II trial of fludarabine monophosphate in patients with mantle-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin’s lymphomas: a single center experience on 18 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

The role of high-dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Fourteen years of high-dose CHOP (ACVB regimen): preliminary conclusions about the treatment of aggressive-lymphoma patients. Hamilton Fairley Award Lecture, European Society for Medical Oncology Meeting, Lisbon, November 21, 1994.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

ESHAP--an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Neutropenia in patients treated with rituximab

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21313

7 January 2021

Identifiers

DOI

10.1002/CNCR.21313

1 reference

6 December 2017

1 reference